文献速递淋巴瘤

加速分割而非常规分割放疗可诱导小鼠B细胞淋巴瘤产生强效T细胞介导的缓解

Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions.
PubMed 文献 · Blood Adv · 2018-01-01

研究在小鼠皮下A20和BL3750淋巴瘤模型中比较加速放疗(4天内10次3 Gy,总剂量30 Gy)与常规放疗(12天内10次3 Gy)的效果,发现加速放疗组完全且持久缓解更多,多数小鼠对肿瘤细胞再挑战抵抗,提示诱导记忆性抗肿瘤免疫;该效应依赖CD8+ T细胞、Rag-2及Batf-3,并与免疫原性细胞死亡标志物高表达相关。

要点

  • 加速放疗(4天10次3 Gy)较常规放疗(12天10次3 Gy)诱导更多完全持久缓解。
  • 加速放疗缓解依赖CD8+ T细胞、Rag-2和Batf-3,免疫缺陷小鼠中未见。
  • 加速放疗增加肿瘤浸润CD4+、CD8+ T细胞和MHCII+CD103+CD11c+树突状细胞,减少耗竭PD-1+Eomes+CD8+ T细胞和调节性T细胞。

核心结论

  • 加速分割局部放疗而非常规分割放疗可诱导T细胞介导的持久缓解,提示其可能为人DLBCL提供有效免疫控制。

研究设计与样本

  • 研究采用小鼠皮下A20和BL3750淋巴瘤模型,比较加速放疗(4天内10次3 Gy,总剂量30 Gy)与常规放疗(12天内10次3 Gy)的疗效及免疫机制。

主要发现

  • 加速放疗组较常规放疗组完全且持久肿瘤缓解更多,多数小鼠对淋巴瘤细胞再挑战抵抗,显示记忆性抗肿瘤免疫。
  • 加速放疗疗效增强与肿瘤细胞坏死多于凋亡及免疫原性细胞死亡标志物钙网蛋白、Hsp70和Hsp90表达相关。
  • 加速放疗诱导的缓解在免疫缺陷Rag-2-/-小鼠、CD8+ T细胞清除小鼠及缺乏CD8α+和CD103+树突状细胞的Batf-3-/-小鼠中未出现。
  • 免疫健全宿主中加速放疗而非常规放疗显著增加肿瘤浸润CD4+和CD8+ T细胞及MHCII+CD103+CD11c+树突状细胞,并相应减少耗竭PD-1+Eomes+CD8+ T细胞和CD4+CD25+FOXP3+调节性T细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conventional local tumor irradiation (LTI), delivered in small daily doses over several weeks, is used clinically as a palliative, rather than curative, treatment for chemotherapy-resistant diffuse large B-cell lymphoma (DLBCL) for patients who are ineligible for hematopoietic cell transplantation. Our goal was to test the hypothesis that accelerated, but not conventional, LTI would be more curative by inducing T cell-mediated durable remissions. We irradiated subcutaneous A20 and BL3750 lymphoma tumors in mice with a clinically relevant total radiation dose of 30 Gy LTI, delivered in 10 doses of 3 Gy over 4 days (accelerated irradiation) or as 10 doses of 3 Gy over 12 days (conventional irradiation). Compared with conventional LTI, accelerated LTI resulted in more complete and durable tumor remissions. The majority of these mice were resistant to rechallenge with lymphoma cells, demonstrating the induction of memory antitumor immunity. The increased efficacy of accelerated LTI correlated with higher levels of tumor cell necrosis vs apoptosis and expression of "immunogenic cell death" markers, including calreticulin, heat shock protein 70 (Hsp70), and Hsp90. Accelerated LTI-induced remissions were not seen in immunodeficient Rag-2 -/- mice, CD8+ T-cell-depleted mice, or Batf-3 -/- mice lacking CD8α+ and CD103+ dendritic cells. Accelerated, but not conventional, LTI in immunocompetent hosts induced marked increases in tumor-infiltrating CD4+ and CD8+ T cells and MHCII+CD103+CD11c+ dendritic cells and corresponding reductions in exhausted PD-1+Eomes+CD8+ T cells and CD4+CD25+FOXP3+ regulatory T cells. These findings raise the possibility that accelerated LTI can provide effective immune control of human DLBCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Dutt S, Atallah MB, Minamida Y, et al. Accelerated, but not conventional, radiotherapy of murine B-cell lymphoma induces potent T cell-mediated remissions. Blood Adv. 2018. PMID: 30301812. doi:10.1182/bloodadvances.2018023119

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。